详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024)

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：梯队期刊

作者：

机构： [1]Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. [2]Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. [3]Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing 100191, China. [4]Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. [5]Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China. [6]Department of Cardiology, the First Affiliated Hospital, Harbin Medical University, Harbin 150001, China. [7]Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. [8]Department of Pharmacy, Evidence-based Pharmacy Center, West China Second Hospital, Sichuan University, Chengdu 610041, China. [9]Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. [10]Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin 150010, China. [11]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. [12]Department of Hematology, Peking University Third Hospital, Beijing 100191, China.

出处：

DOI：

ISSN：

摘要：

Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment. A multidisciplinary consensus working group was established, comprising 35 members from the fields of hematology, cardiovascular disease, cardio-oncology, clinical pharmacy, and evidence-based medicine. This evidence-based expert consensus was formulated using an evidence-based approach and the Delphi method. The Joanna Briggs Institute Critical Appraisal (JBI) tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach were used to rate the quality of evidence and grade the strength of recommendations, respectively. This consensus provides practical recommendations for BTKis medication based on nine aspects within three domains, including the management of common adverse drug events such as bleeding, cardiovascular events, and hematological toxicity, as well as the management of drug-drug interactions and guidance for special populations. This multidisciplinary expert consensus could contribute to promoting a multi-dimensional, comprehensive and standardized management of BTKis.Copyright ©2024 Chinese Journal of Cancer Research. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. [2]Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. [3]Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing 100191, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. [2]Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. [3]Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University, Beijing 100191, China. [10]Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin 150010, China. [11]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. [12]Department of Hematology, Peking University Third Hospital, Beijing 100191, China. [*1]Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China [*2]Department of Hematology, Peking University Third Hospital, Beijing 100191, China [*3]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China [*4]Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin 150010, China

推荐引用方式(GB/T 7714)：

APA：

MLA：